[go: up one dir, main page]

MX9800190A - Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t. - Google Patents

Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t.

Info

Publication number
MX9800190A
MX9800190A MX9800190A MX9800190A MX9800190A MX 9800190 A MX9800190 A MX 9800190A MX 9800190 A MX9800190 A MX 9800190A MX 9800190 A MX9800190 A MX 9800190A MX 9800190 A MX9800190 A MX 9800190A
Authority
MX
Mexico
Prior art keywords
cell mediated
preparations
treatment
mediated diseases
methods
Prior art date
Application number
MX9800190A
Other languages
English (en)
Other versions
MXPA98000190A (es
Inventor
Irun R Cohen
Dana Elias
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MXPA98000190A publication Critical patent/MXPA98000190A/es
Publication of MX9800190A publication Critical patent/MX9800190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

Emulsiones de lipidos metabolizables, tales como Intralipid y LIpofundin, son vehículos excelentes para terapia peptídica de enfermedades autoinmunes y otras enfermedades o condiciones mediadas por células T, TH1, ya que promueve un cambio de citocinas de TH1 o TH2", dichas emulsiones se pueden usar junto con un antígeno reconocido por células T inflamatorias asociadas con la patogénesis de una enfermedad o condicion mediada por células T para el tratamiento terapéutico de dicha condicion.
MX9800190A 1995-07-05 1996-07-02 Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t. MX9800190A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
IL114458 1995-07-05
PCT/US1996/011373 WO1997002016A1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases

Publications (2)

Publication Number Publication Date
MXPA98000190A MXPA98000190A (es) 1998-04-01
MX9800190A true MX9800190A (es) 1998-04-30

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800190A MX9800190A (es) 1995-07-05 1996-07-02 Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t.

Country Status (22)

Country Link
EP (1) EP0837672B9 (es)
JP (2) JP4357595B2 (es)
KR (1) KR100435040B1 (es)
CN (1) CN1102382C (es)
AT (1) ATE254451T1 (es)
AU (1) AU714970B2 (es)
CA (1) CA2226013C (es)
CZ (1) CZ298A3 (es)
DE (1) DE69630787T2 (es)
DK (1) DK0837672T3 (es)
ES (1) ES2211963T3 (es)
HR (1) HRP960315A2 (es)
HU (1) HU223081B1 (es)
IL (2) IL114458A0 (es)
MX (1) MX9800190A (es)
NO (1) NO320363B1 (es)
PT (1) PT837672E (es)
SI (1) SI0837672T1 (es)
UY (1) UY24275A1 (es)
WO (1) WO1997002016A1 (es)
YU (1) YU40796A (es)
ZA (1) ZA965666B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2389301T3 (es) 2002-05-21 2012-10-25 Irun R. Cohen Vacunas de ADN que codifican proteínas de choque térmico
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
EP1687423A4 (en) * 2003-11-24 2007-04-18 Yeda Res & Dev HSP60 PEPTIDE FRAGMENT-ENCODING DNA VACCINES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
AU2006293420B2 (en) 2005-09-22 2011-06-30 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
EP3448415A4 (en) * 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients

Also Published As

Publication number Publication date
KR100435040B1 (ko) 2004-08-18
CZ298A3 (cs) 1998-06-17
ES2211963T3 (es) 2004-07-16
NO980013D0 (no) 1998-01-02
CN1193907A (zh) 1998-09-23
SI0837672T1 (en) 2004-04-30
PT837672E (pt) 2004-03-31
EP0837672B1 (en) 2003-11-19
EP0837672B9 (en) 2005-06-15
JP4357595B2 (ja) 2009-11-04
ATE254451T1 (de) 2003-12-15
EP0837672A4 (en) 1999-01-27
NO980013L (no) 1998-02-19
HU223081B1 (hu) 2004-03-29
HRP960315A2 (en) 1998-02-28
DK0837672T3 (da) 2004-03-22
IL114458A0 (en) 1995-11-27
HUP9802834A2 (hu) 1999-03-29
EP0837672A1 (en) 1998-04-29
KR19990028738A (ko) 1999-04-15
WO1997002016A1 (en) 1997-01-23
NO320363B1 (no) 2005-11-28
IL122755A (en) 2004-07-25
ZA965666B (en) 1997-01-27
IL122755A0 (en) 1998-08-16
UY24275A1 (es) 2000-12-29
DE69630787D1 (de) 2003-12-24
AU714970B2 (en) 2000-01-13
JP2009242412A (ja) 2009-10-22
CN1102382C (zh) 2003-03-05
JPH11508899A (ja) 1999-08-03
HUP9802834A3 (en) 2001-08-28
YU40796A (sh) 1998-11-05
DE69630787T2 (de) 2004-10-07
CA2226013A1 (en) 1997-01-23
AU6484496A (en) 1997-02-05
CA2226013C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
ZA965666B (en) Preparations and methods for the treatment of t cell mediated diseases
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
EP0751781A4 (en) METHOD FOR PREVENTING OR TREATING A DISEASE, CHARACTERIZED BY THE NEOPLASTIC CELLS EXPRESSING CD40
AU3844297A (en) Treatment of autoimmune diseases
SI1270595T1 (sl) Protitelo proti CCR4 in njegov fragment
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
MXPA03001167A (es) Proteinas y peptidos de tension y metodos para su uso.
Chen What's new about the mechanism of methotrexate action in psoriasis?
PT782630E (pt) Gene da doenca poliquistica do rim
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
AU6953296A (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Ishida et al. Nutritional and immunological assessment in patients with malignant obstructive jaundice--the influence of preoperative biliary decompression and abdominal surgery
Wrigley et al. Normal cerebral function with bilateral carotid occlusion
Novales-Li In vitro immunopharmacologic effect of suramin on modifying Th-subset cytokine levels in splenocytes and T-cell clones: a therapeutic application for autoimmune disease
Plana Tematica delirante psicotica en psicopatologia de la expresion pictoria. Mitologemas.
WO2001038394A3 (en) Polypetptides and methods for thymic vaccination
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології
UA34283A (uk) Спосіб діагностики порушень імунологічного статусу у людини та тварин